Boeh Mannheim Product Recall
German pharmaceutical company Boehringer Mannheim has ordered the complete recall of all products of the Comsat (trimoxazole) family and suspended the whole pharmaceutical production at its Thane, India, manufacturing plant.
The firm said that four batches of the anti-infective Comsat forte, produced by the firm's Indian subsididary for the Indian market, were contaminated with glibencamide, an antidiabetic agent, "due to unknown circumstances" in the Boehringer Mannheim plant at Thane.
70 patients have had serious illness and there have been two deaths alleged to have occurred in connection with this contamination, commented Boehringer Mannheim. The firm said that it is investigating the incident, and has warned the public, medical professions and the distribution channels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze